Although there are some current clinical trials using the γ-secretase inhibitors for diseases as diverse as Alzheimer's and leukemia [47], our experimental studies does not support the potential beneficial effect of these drugs in AngII-mediate renal diseases. Here, AGT is linked to kidney disorder.